AstraZeneca has inked a $555 million agreement with San Francisco-based Algen Biotechnologies to harness Algen's AI-driven AlgenBrain platform targeting immunology drug discovery. The partnership aims to accelerate the identification of novel therapeutic targets by combining single-cell CRISPR gene editing with advanced artificial intelligence. This collaboration exemplifies the growing integration of AI technologies to enhance target validation and streamline drug development efforts within the immunology sector.